@misc{indiciae7ee2d9b533d7,
  title = {Long-term follow-up of a phase 1/2 trial of anti-GDF-15 antibody visugromab plus anti-PD-1 antibody nivolumab in anti-PD-1/-L1 relapsed/refractory solid tumors.},
  author = {Ignacio Melero and Mar\&\#xed;a de Miguel and Elena Garralda Cabanas and Guillermo de Velasco and Markus Joerger and Juan Mart\&\#xed;n-Liberal and Maria Reig and David K\&\#xf6;nig and Joerg Trojan and Maria-Elisabeth Goebeler and Martin Schuler and Guzman Alonso and Reinhard Dummer and Maria E Rodr\&\#xed;guez-Ruiz and Ram\&\#xf3;n Yarza and Giulia Pretelli and Jorge Esteban-Villarubia and Kira-Lee Koster and Paula Sabat Viltro and Marco Sanduzzi-Zamparelli and Heinz L\&\#xe4;ubli and Christine Koch and Cyrus Sayehli and Tanja Gromke and Fabricio Racca and Egle Ramelyte and Peter R Galle and Andrea Necchi and Martin Reck and Zlatko Trajanoski and Hubert Hackl and Falk Gogolla and Jaclyn Billing and Teresa Sattmann and J\&\#xf6;rg Wischhusen and Christine Schuberth-Wagner and Julia Akdemir and Felix S Lichtenegger and Alexandra Auckenthaler and Marlene Fox and Kathrin Klar and Petra Fettes and Mara Liebig and Aasim Amin and Sheena Sachdeva and Frank Hermann and Eugen Leo},
  year = {2026},
  doi = {10.1186/s13045-026-01818-2},
  url = {https://pubmed.ncbi.nlm.nih.gov/42426863/},
  note = {Source identifier: 42426863}
}